Prescription items are NON-RETURNABLE and NON REFUNDABLE Dormosedan Vial Dormosedan (R) is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration. Recommended dosages only. Always follow the directions for dosing and administration from your veterinarian. For Sedation: Administer Dormosedan (R) IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan (R) per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation. For Analgesia: Administer Dormosedan (R) IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan (R) per 100 kg or 220 lb), depending on the depth and duration of analgesia required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia. For Both Sedation and Analgesia: Administer Dormosedan (R) IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan (R) per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required. Before and after injection, the animal should be allowed to rest quietly. Storage Conditions: Store at controlled room temperature 15°-30°C (59°-86°F) in the absence of light. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Dormosedan (R) should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur. Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals. Side Effects: Horses treated with Dormosedan (R) exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45-60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing. Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects. Human Warning: Care should be taken to assure that detomidine hydrochloride is not inadvertently ingested as safety studies have indicated that the drug is well absorbed when administered orally. Standard ocular irritation tests in rabbits using the proposed market formulation have shown detomidine hydrochloride to be nonirritating to eyes. Primary dermal irritation tests in guinea pigs using up to 5 times the proposed market concentration of detomidine hydrochloride on intact and abraded skin have demonstrated that the drug is nonirritating to skin and is apparently poorly absorbed dermally. However, in accordance with prudent clinical procedures, exposure of eyes or skin should be avoided and affected areas should be washed immediately if exposure does occur. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using loaded syringes to prevent accidental self-injection. Keep out of reach of children and animals.
« Read less
Prescription items are NON-RETURNABLE and NON REFUNDABLE Dormosedan Vial Dormosedan (R) is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfu
...Read more »